AndreaBozzo/ceres-open-data-index huggingface dataset:
MD iMAP: Maryland Long Term Care Assisted Living - Geriatric Care Hospitals

This is a MD iMAP hosted service layer. Find more information at http://imap.maryland.gov. OP&R organizes and prepares for public health and medical emergencies through statewide partnerships with public -  private and government agencies to coordinate an effective emergency response for the health and safety of all residents of Maryland. Last Updated:  10/06/2014 Feature Service Layer Link: http://geodata.md.gov/imap/rest/services/Health/MD_LongTermCareAssistedLiving/FeatureServer/2 ADDITIONAL LICENSE TERMS: The Spatial Data and the information therein (collectively "the Data") is provided "as is" without warranty of any kind either expressed implied or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct indirect incidental consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Compound 527037: N-(2-phenylethyl)-N-methyl-benzamide

Chemical compound data from PubChem database. IUPAC Name: N-methyl-N-(2-phenylethyl)benzamide. Molecular Formula: C16H17NO. Molecular Weight: 239.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529814: Butanal, 2-methyl, 2,4,6-trichlorophenyl hydrazone

Chemical compound data from PubChem database. IUPAC Name: 2,4,6-trichloro-N-(2-methylbutylideneamino)aniline. Molecular Formula: C11H13Cl3N2. Molecular Weight: 279.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526794: Palmitic acid, 2-tert-butyldimethylsilyloxy-, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 2-[tert-butyl(dimethyl)silyl]oxyhexadecanoate. Molecular Formula: C23H48O3Si. Molecular Weight: 400.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401017-T1: [Translated] COUNTERTOP FOR INDUSTRIAL CATERING KITCHENS

A worktop (1) for industrial catering kitchens formed by a flat supporting frame (2) of essentially rectangular shape and which extends in horizontal position at a predetermined height from the ground, by four legs (3) resting on the ground fastened to the flat frame (2) at the four vertexes of the latter, and finally by an upper horizontal top (4) stably fastened to the flat supporting frame (2); the flat supporting frame (2) consisting of a flat metallic top (5) of essentially rectangular shape which has four side borders (5b, 5c) folded on themselves essentially C-shaped or O-shaped so as to define the four sides of the flat frame (2), and by four angular elements (6) of plastic material which are positioned at the four vertexes of the rectangle defining the external perimeter of the flat plate (5) and which are immovably entrapped underneath the four side borders (5b, 5c) of the flat plate (5).
Bridging case-control studies and randomized trials

Randomized trials and observational studies, such as case-control studies, are often seen as opposing approaches. However, in many instances results obtained by different designs may complement each other. For instance, case-control studies on aetiology of disease may help to give the direction of future trials. In this commentary, the author discusses the purpose of randomization and observation, and under which conditions one design may be preferred to another. Randomization is useful to combat 'confounding by indication', and is therefore the design of choice for most therapeutic trials. When this confounding is not an issue, as in studies of genetic risk factors or side-effects, then case-control studies are preferred.
Compound 526745: alpha-terpineyl beta-D-glucopyranoside, TFA

Chemical compound data from PubChem database. IUPAC Name: [6-[2-(4-methylcyclohex-3-en-1-yl)propan-2-yloxy]-3,4,5-tris[(2,2,2-trifluoroacetyl)oxy]oxan-2-yl]methyl 2,2,2-trifluoroacetate. Molecular Formula: C24H24F12O10. Molecular Weight: 700.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525726: (p-Methylbenzylidene)-heptyl-amine

Chemical compound data from PubChem database. IUPAC Name: N-heptyl-1-(4-methylphenyl)methanimine. Molecular Formula: C15H23N. Molecular Weight: 217.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
SHIP Early Prenatal Care 2010-2021

Early Prenatal Care - This indicator shows the percentage of pregnant women who receive prenatal care beginning in the first trimester. Inadequate prenatal care services have been linked to higher rates of infant mortality, low birth weight and pre-term deliveries. While Maryland as a whole ranks better than the National average and the Healthy People 2020 Target, disparities still exist. Due to the change in methodology for collecting information on the Maryland birth certificate, data collected in 2010 and after are not comparable to data collected in earlier years. <a href ="https://health.maryland.gov/pophealth/Documents/SHIP/SHIP%20Lite%20Data%20Details/Early%20Prenatal%20Care.pdf" > Link to Data Details </a>
Patent AT-E400529-T1: [Translated] METHOD FOR BIOLOGICALLY TREATING SOLID MATERIALS IN AN UNSTIRRED SURFACE BIOREACTOR

A method of biotreating and recovering metal values from metal-bearing refractrory sulfide ore using a nonstirred surface bioreactor is provided. According to the method, the surface of a plurality of coarse substrates is coated with a solid material to be biotreated to form a plurality of coated coarse substrates. The coarse substrates have a particle size greater than about 0.3 cm and the solid material to be biotreated has a particle size less than about 250 μm. A nonstirred surface reactor is then formed by stacking the plurality of coated coarse substrates into a heap or placing the plurality of coated coarse substrates into a tank so that the void volume of the reactor is greater than or equal to about 25%. The solid material is biotreated in the surface bioreactor until the undesired compound in the solid material is degraded to a desired concentration.
San Francisco – SF Div: Drug-Related Emergency Department Visits, 2004-2011 - Seeking Detox

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving patients seeking detox in the San Francisco division of the  metropolitan area, covering 2004-2011. This includes nonemergency requests made through the ED for admission to detoxification unit, visits to obtain medical clearance before being incarcerated, and acute emergencies where an individual is experiencing withdrawal symptoms and requests detox. These estimates do not include patients who seek or enter the hospital\'s detox unit through other avenues.
CDC WONDER: Cancer Statistics

<p>The United States Cancer Statistics (USCS) online databases in WONDER provide cancer incidence and mortality data for the United States for the years since 1999, by year, state and metropolitan areas (MSA), age group, race, ethnicity,  sex, childhood cancer classifications and cancer site. Report case counts, deaths, crude and age-adjusted incidence and death rates,  and 95% confidence intervals  for rates.  The USCS  data are the official federal statistics on cancer incidence from registries having high-quality data and cancer mortality statistics for 50 states and the District of Columbia. USCS are produced by the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI), in collaboration with the North American Association of Central Cancer Registries (NAACCR). Mortality data are provided by the Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), National Vital Statistics System  (NVSS).</p>
Patent AT-E401424-T1: [Translated] METHOD FOR IDENTIFYING NUCLEIC ACID LIGANDS FOR TISSUE TARGETS

This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to peripheral blood mononuclear cells (PBMC), fibrin clots and carotid arteries are described.
Provider Network Data: 2021 Quarter 3

This Provider Network Data contains information on individual and institutional providers participating in health plan networks from July through September 2021. Plan network data is collected from Medicaid, Commercial, and Exchange plans on a quarterly basis by the Department of Health, including managed care plans, as well as PPO/EPO plans.

For more information, please visit: <a href=https://pndslookup.health.ny.gov>https://pndslookup.health.ny.gov</a>
NNDSS - TABLE 1OO. Viral hemorrhagic fevers, Lujo virus to Viral hemorrhagic fevers, Marburg virus

NNDSS - TABLE 1OO. Viral hemorrhagic fevers, Lujo virus to Viral hemorrhagic fevers, Marburg virus – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents..

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
Compound 525893: N,N-Dimethyl-N'-(4-nitrophenyl)-pivalamidine

Chemical compound data from PubChem database. IUPAC Name: N,N,2,2-tetramethyl-N'-(4-nitrophenyl)propanimidamide. Molecular Formula: C13H19N3O2. Molecular Weight: 249.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525319: Lactulose, octakis(trimethylsilyl) ether (isomer 1)

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[2-trimethylsilyloxy-2,5-bis(trimethylsilyloxymethyl)-4-[3,4,5-tris(trimethylsilyloxy)-6-(trimethylsilyloxymethyl)oxan-2-yl]oxyoxolan-3-yl]oxysilane. Molecular Formula: C36H86O11Si8. Molecular Weight: 919.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400566-T1: [Translated] BENZOFURANES AND BENZOTHIOPHENES

Chemical patent from PubChem database. Patent Number: AT-E400566-T1. Title: Polymorphic Forms of Active Compounds. Filing Date: 2002-12-15. Inventors: Patel, Amit, Jones, Michael. Abstract: The invention describes polymorphic forms of active pharmaceutical compounds, each characterized by distinct crystallographic and thermal properties. IPC Classifications: B01J, C07C, C07D. This patent covers 44 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Children’s Bureau FY2014 Discretionary Grants

(revised 1-9-2014)

The Children's Bureau is currently forecasting and publishing FY 2014 discretionary grant funding opportunities. Please check the websites below regularly, as this information is subject to change.

FORECASTS Information about planned FY 2014 FOAs is now available on the U.S. Department of Health and Human Services Grants Forecast website: /hhsgrantsforecast/
  
  

 To find the Children's Bureau's FOA forecasts, go to the forecast website and enter the title or Funding Opportunity Number (FON) in the search box.

FOAs As they are published, CB discretionary grant FOAs can be accessed here- /grants/open/foa/office/acyf_cb

NOTE: beginning January 1, 2012, ACF requires electronic submission of applications for discretionary grants at http://www.Grants.gov
  
  

.  Information on applying electronically is available at http://www.Grants.gov
  
  

. Applicants that do not have an Internet connection or sufficient computing capacity to upload large documents (files) to the Internet may contact ACF for an exemption that will allow these applicants to submit an application in paper format. Information on requesting an exemption from electronic application submission will be published in FY2014 discretionary grant funding opportunity announcements.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 525564: N,N-Dimethyl-N'-(3-bromophenyl)-p-methylbenzamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(3-bromophenyl)-N,N,4-trimethylbenzenecarboximidamide. Molecular Formula: C16H17BrN2. Molecular Weight: 317.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400616-T1: [Translated] FIBER REACTIVE DYES

<CHEM> wherein the definition of D, and Z have the same meaning as given in the description. The fiber reactive dyestuff of the present invention is suitable for dyeing and printing on cellulose fiber or fiber materials containing cellulose. Dyed material with various excellent properties in dyed color can be obtained, showing especially outstanding performance in the property of wash fastness.
Conservation of the binding site for the arginine repressor in all bacterial lineages

Background:
          The arginine repressor ArgR/AhrC is a transcription factor universally conserved in bacterial genomes. Its recognition signal (the ARG box), a weak palindrome, is also conserved between genomes, despite a very low degree of similarity between individual sites within a genome. Thus, the arginine repressor is different from two other universal transcription factors - HrcA, whose recognition signal is very strongly conserved both within and between genomes, and LexA/DinR, whose signal is strongly conserved within, but not between, genomes. The arginine regulon is well studied in Escherichia coli and to some extent in Bacillus subtilis and some other genomes. Here, we apply the comparative genomic approach to the prediction of the ArgR-binding sites in all completely sequenced bacterial genomes.
        
        
          Results:
          Orthologs of ArgR/AhrC were identified in the complete genomes of E. coli, Haemophilus influenzae, Vibrio choleras, B. subtilis, Mycobacterium tuberculosis, Thermotoga maritima, Chlamydia pneumoniae and Deinococcus radiodurans. Candidate arginine repressor binding sites were identified upstream of arginine transport and metabolism genes.
        
        
          Conclusions:
          We found that the ArgR/AhrC recognition signal is conserved in all genomes that contain genes encoding orthologous transcription factors of this family. All genomes studied except M. tuberculosis contain ABC transport cassettes (related to the Art system of E. coli) belonging to the candidate arginine regulons.
Round 4 Guide for Writing “No” Narratives and Rationale Statements

Child and Family Services Reviews reviewers must complete short “No” Narratives and longer Rationale Statements as part of completing the Onsite Review Instrument and Instructions (OSRI) and rating its items and outcomes. This guide is recommended for use by reviewers to ensure that “No” Narratives and Rationale Statements succinctly and comprehensively provide the information required to support answers to OSRI questions.

Metadata-only record linking to the original dataset. Open original dataset below.
The process of genome shrinkage in the obligate symbiont

Background
          Very small genomes have evolved repeatedly in eubacterial lineages that have adopted obligate associations with eukaryotic hosts. Complete genome sequences have revealed that small genomes retain very different gene sets, raising the question of how final genome content is determined. To examine the process of genome reduction, the tiny genome of the endosymbiont Buchnera aphidicola was compared to the larger ancestral genome, reconstructed on the basis of the phylogenetic distribution of gene orthologs among fully sequenced relatives of Escherichia coli and Buchnera.
        
        
          Results
          The reconstructed ancestral genome contained 2,425 open reading frames (ORFs). The Buchnera genome, containing 564 ORFs, consists of 153 fragments of 1-34 genes that are syntenic with reconstructed ancestral regions. On the basis of this reconstruction, 503 genes were eliminated within syntenic fragments, and 1,403 genes were lost from the gaps between syntenic fragments, probably in connection with genome rearrangements. Lost regions are sometimes large, and often span functionally unrelated genes. In addition, individual genes and regulatory regions have been lost or eroded. For the categories of DNA repair genes and rRNA genes, most lost loci fall in regions between syntenic fragments. This history of gene loss is reflected in the sequences of intergenic spacers at positions where genes were once present.
        
        
          Conclusions
          The most plausible interpretation of this reconstruction is that Buchnera lost many genes through the fixation of large deletions soon after the acquisition of an obligate endosymbiotic lifestyle. An implication is that final genome composition may be partly the chance outcome of initial deletions and that neighboring genes influence the likelihood of loss of particular genes and pathways.
Isolation and characterization of new

Background
          Nuclear pore complexes (NPCs) are essential for facilitated, directional nuclear transport; however, the mechanism by which ~30 different nucleoporins (nups) are assembled into NPCs is unknown. We combined a genetic strategy in Saccharomyces cerevisiae with Green Fluorescence Protein (GFP) technology to identify mutants in NPC structure, assembly, and localization. To identify such mutants, a bank of temperature sensitive strains was generated and examined by fluorescence microscopy for mislocalization of GFP-tagged nups at the non-permissive temperature.
        
        
          Results
          A total of 121 mutant strains were isolated, with most showing GFP-Nic96 and Nup170-GFP mislocalized to discrete, cytoplasmic foci. By electron microscopy, several mutants also displayed an expansion of the endoplasmic reticulum (ER). Complementation analysis identified several mutant groups with defects in components required for ER/Golgi trafficking (sec13, sec23, sec27, and bet3). By directed testing, we found that mutant alleles of all COPII components resulted in altered GFP-Nup localization. Finally, at least nine unknown complementation groups were identified that lack secretion defects.
        
        
          Conclusion
          The isolation of sec mutants in the screen could reflect a direct role for vesicle fusion or the COPII coat during NPC assembly; however, only those sec mutants that altered ER structure affected Nup localization. This suggests that the GFP-Nup mislocalization phenotypes observed in these mutants were the indirect result of overproliferation of the ER and connected outer nuclear envelope. The identification of potentially novel mutants with no secretory defects suggests the distinct GFP-Nup localization defects in other mutants in the collection will provide insights into NPC structure and assembly.